Skip to content

Psilocybin: all studies

Page 357 of 440: studies 3,561 to 3,570 of 4,399, newest first. Back to the psilocybin overview

Research

ANÁLISE DO USO DE SUBSTÂNCIAS PSICODÉLICAS NO TRATAMENTO DA DEPRESSÃO: UMA REVISÃO INTEGRATIVA DE LITERATURA

Revista Ibero-Americana de Humanidades, Ciências e Educação November 19, 2024 Diogo Nelson Rodrigues Noronha, Flávia Avelino Galvão de MouraMoura, Gabriel Teixeira Guimarães da Fonseca et al.

O estudo buscou analisar o efeito dos psicodélicos como um meio alternativo para o tratamento do transtorno depressivo maior. Trata se de uma revisão integrativa de literatura na qual foram selecionados os descritores “psychedelic” “depression” adicionados com o operador booleano “and” entre esses nas bases de dados National Library of Medicine (PUBMED) e na Biblioteca Virtual De Saúde (BVS)....

Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA.

Journal of Affective Disorders November 15, 2024 Abigail E. Calder, Gregor Hasler 20 citations

Studies of psychedelic-assisted therapy with LSD, psilocybin, MDMA, and related substances show clinical promise but inadequately assess side effects. Measuring side effects is challenging because they are not always easily differentiated from treatment effects or disease symptoms and show high heterogeneity, variable duration and impact, and sensitivity to context. A systematic questionnaire...

DOI: 10.1016/j.jad.2024.08.091 (opens in new tab) Full text (opens in new tab) Adverse effects Psychedelics Safety Side effects +5

The Effect of Psilocybe cubensis on Spatial Memory and BDNF Expression in Male Rats Exposed to Chronic Unpredictable Mild Stress

Journal of Psychoactive Drugs November 13, 2024 Reza Ghaffarzadegan, Mokhtar Karimi, Behnaz Hedayatjoo et al. 6 citations

Psilocybin-containing mushrooms, commonly known as magic mushrooms, drastically affect mental processing, cognitive functioning, and the mood state. In the present study, we investigated the effect of the Psilocybe cubensis extract on spatial memory and the brain-derived neurotrophic factor (BDNF) in rats exposed to chronic unpredictable mild stress (CUMS). The duration of CUMS was 4 weeks....

Explorando las terapias psicodélicas: Una revisión sistemática de la eficacia de la psilocibina en el tratamiento de la depresión

MLS Psychology Research November 12, 2024 Lucía Villalba Díez

The main objective is to verify if the administration of psilocybin is effective for the treatment of depression. In addition, the aim is to verify whether psilocybin is more effective compared to escitalopram as well as to verify the existence of adverse effects due to the treatment. Currently, mental health faces global challenges; Proof of this is the 25% increase in depressive disorders...

Advances in Psychedelic Therapeutics: Novel Prodrugs and Derivatives for Enhanced Mental Health Treatment.

ACS Medicinal Chemistry Letters November 11, 2024 Robert B. Kargbo

High Resolution Image Download MS PowerPoint Slide Recent innovations in psychedelic research have led to the development of novel compounds designed to enhance the therapeutic potential of psilocin and related tryptamines. This Patent Highlight reviews three essential patents that focus on improving the stability, bioavailability, and efficacy of these compounds for treating mental health...

Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies

Journal of Psychoactive Drugs November 6, 2024 Aleksandra Barstowe, Petri Kajonius 8 citations

Psychedelic-assisted therapy is becoming increasingly acknowledged as an effective therapeutic intervention for various psychiatric illnesses. However, the evaluation of masking success is rarely reported in trials. The objective of the present systematic review was to evaluate placebo-control and masking in studies exploring psychedelic-assisted therapy. Nine (k = 9) studies dating between...

DOI: 10.1080/02791072.2024.2424272 (opens in new tab) Masking influences Placebo control Psychedelics Systematic review +5

Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use

Journal of Psychoactive Drugs November 6, 2024 Rotem Petranker, Valentyn Sobolenko, Zeina Beidas et al. 9 citations

Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described the characteristics, motivations and practices of microdosers, the differences between individuals that only microdose and those that use both micro and macrodoses of psychedelics remain unexplored. In an online survey, we collected data of 6193...

Proteomic analysis of psychedelic mushroom isolate and exploring potential antimicrobial peptides against bacteria.

Natural Product Research November 5, 2024 Balakrishnan Karthiyayini, Arulprakasam Karthick Raja, Sivaraj Arthi et al. 1 citation

Psychedelic mushrooms belonging to basidiomycota have gained prominence in research due to the range of hallucinogenic compounds. To combat the challenge of antimicrobial resistance, exploring alternative antimicrobial peptides has become crucial. In this study, we present the proteomic analysis of psychedelic mushroom. Psilocybe cubensis was identified by molecular characterisation using the...

DOI: 10.1080/14786419.2024.2423045 (opens in new tab) Full text (opens in new tab) Proteomics Psilocybin-mushrooms Antibiotic-resistance Bacterial-pathogens +5

Will Psychedelics Propel Your Career? Exploring the Potential Impact of Psychedelics on Work, Productivity and Well-Being

Human Capital Leadership Review November 1, 2024 Jonathan Westover

With growing research demonstrating the therapeutic potential of psychedelics such as psilocybin and MDMA in treating mental health conditions, interest is mounting around potential applications beyond health. This article explores emerging evidence on the impact of psychedelics in key domains relevant to careers and the workplace including creativity, focus, stress and burnout, leadership,...

Psychoactive substances for the treatment of neuropsychiatric disorders.

Asian Journal of Psychiatry November 1, 2024 Zifan Zhen, Xueqiang Sun, Shiying Yuan et al. 8 citations

In the contemporary landscape of psychiatric medicine, critical advancements have been noted in the utilization of psychoactive substances such as hallucinogens, 3,4-methylenedioxymethamphetamine (MDMA), and ketamine for the treatment of severe mental health disorders. This review provides a detailed evaluation of these substances, focusing on their mechanisms of action and the profound...

DOI: 10.1016/j.ajp.2024.104193 (opens in new tab) Full text (opens in new tab) Ketamine MDMA Neuropsychiatric disorders Psychedelics hallucinogens +6